GNI Group Ltd
3G6
Company Profile
Business description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Contact
Shinjuku Park Tower
3-7-1 Nishi-Shinjuku
Shinjuku-ku
Tokyo163-1030
JPNT: +81 353263097
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
896
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,794.49 | 34.80 | -0.44% |
DAX 40 | 24,038.96 | 216.35 | -0.89% |
Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
FTSE 100 | 8,978.33 | 37.21 | 0.42% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,585.53 | 45.14 | -0.22% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,259.75 | 20.71 | -0.33% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |